Insider Buying: Forte Biosciences, Inc. (NASDAQ:FBRX) CFO Purchases $124,952.70 in Stock

Forte Biosciences, Inc. (NASDAQ:FBRX) CFO Antony A. Riley acquired 22,514 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was acquired at an average cost of $5.55 per share, for a total transaction of $124,952.70. Following the completion of the acquisition, the chief financial officer now owns 30,776 shares of the company’s stock, valued at $170,806.80. This trade represents a 272.50 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Forte Biosciences Stock Up 2.3 %

Shares of Forte Biosciences stock opened at $16.00 on Monday. Forte Biosciences, Inc. has a twelve month low of $4.11 and a twelve month high of $21.25. The firm’s 50-day moving average price is $5.91 and its 200 day moving average price is $2.73.

Analysts Set New Price Targets

Separately, Chardan Capital lifted their price target on shares of Forte Biosciences from $3.00 to $64.00 and gave the company a “buy” rating in a research note on Friday, November 15th.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.